Hepion Pharmaceuticals, Inc.
(NASDAQ : HEPA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc. -2.89%21.8714.1%$128.69m
AMRNAmarin Corp. Plc -2.93%14.241.7%$96.58m
CTLTCatalent, Inc. -2.69%51.042.2%$71.51m
JAZZJazz Pharmaceuticals Plc -0.55%112.482.3%$62.14m
UTHRUnited Therapeutics Corp. -0.19%100.6014.3%$59.37m
GWPHGW Pharmaceuticals Plc -3.01%101.326.2%$55.44m
AXSMAxsome Therapeutics, Inc. -3.97%78.421.9%$48.11m
PRGOPerrigo Co. Plc -3.76%49.876.8%$47.47m
HZNPHorizon Therapeutics Plc -0.53%33.886.6%$45.21m
RVMDRevolution Medicines, Inc. -4.23%30.800.0%$43.57m
ZGNXZogenix, Inc. 1.27%23.999.4%$40.78m
MNKMallinckrodt Plc 3.87%4.1720.9%$37.56m
ENDPEndo International Plc -3.82%5.428.8%$37.53m
ICPTIntercept Pharmaceuticals, Inc. 0.47%85.7916.9%$35.98m
ICLRICON plc -0.81%155.414.2%$32.24m

Company Profile

Hepion Pharmaceuticals, Inc. engages in the development and commercialization of pleiotropic drug therapy for the treatment of chronic liver disease. It focuses on the development of its product candidate CRV431, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.